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Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis have emerged as important infections in South
Africa among patients infected with human immunodeﬁciency virus (HIV). In the face of this new epidemic, South Africa
must rededicate itself to the task of tuberculosis control and treatment with a rapid, multifaceted approach. Prioritiesinclude
expansion of second-line treatment capacity, investment in clinical laboratories, a system to ensure supervised treatment for
all patients, and enhancement of infection control procedures. In New York City, where drug-resistant tuberculosis emerged
2 decades ago—also in the context of a large HIV-infected population and an underfunded public health infrastructure—
similar steps were successful in leading to the rapid decrease in rates of drug resistance among tuberculosis isolates. With
reﬁnements based on local resource constraints, urgent measures could potentially arrest the alarming increase in multidrug-
resistant and extensively drug-resistant tuberculosis cases in South Africa. Unlike many countries in sub-Saharan Africa,
South Africa has the capacity to mount a rapid and large-scale response before drug-resistant tuberculosis envelops a much
larger and far poorer region.
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The rise of multidrug-resistant tubercu-
losis (MDR-TB) and extensively drug-re-
sistant tuberculosis (XDR-TB) in South
Africa among patients with HIV infection
is a grave and urgent threat. As South Af-
rica takes steps to respond, there are im-
portant lessons to be drawn from New
York City (NYC), where, 2 decades ago,
drug-resistant tuberculosis also emerged
among patients with HIV infection [1, 2].
It is striking that many of the same con-
ditions that fueled the rise of drug-resis-
tant tuberculosis in NYC also underlie the
current epidemic of MDR-TB and XDR-
TB in South Africa. These include a large
and undertreated HIV-infected popula-
tion, inadequate infection control in hos-
pitals and clinics, and a public health in-
frastructure not equipped to ensure that
patients complete treatment courses. Al-
though important differences should not
be minimized, theexperienceofNYCpro-
vides potentially important insights for
South Africa as it shapes its own unique
response.
MDR-TB AND XDR-TB IN
SOUTH AFRICA
When I arrived in KwaZulu-Natal, South
Africa, in August of 2006, it was already
apparent, from published reports, that
drug-resistanttuberculosiswasdeeplyem-
bedded in the province [3]. But the di-
mensions of the crisis on the ground were
not apparent to me until one day in Jan-
uary 2007, when I met Precious Cele (ﬁc-
titious name), a 35-year-old woman with
HIV infection who, 2 months before, had
received a diagnosis of smear-positivepul-
monary tuberculosis. It was her ﬁrst epi-
sode of tuberculosis, and she had been
prescribedstandard4-drugchemotherapy,
which she had dutifully taken. However,
duringtreatment,hercoughpersisted,and
her weight fell by 7 kg (15 lb). The day I
met her, the laboratory conﬁrmedthatshe
had MDR-TB (deﬁned as infection with
Mycobacterium tuberculosis with resistance
to isoniazid and rifampicin), and we
sought urgent initiation of second-linetu-
berculosis treatment at the only public
hospital in the province whereitwasavail-
able. However, we learned that in front of
her were ∼100 other patients also waiting
for initiation of treatment for MDR-TB
and XDR-TB.
Although South Africa has committed
substantial resources to respond to the
growing crisis of drug-resistant tubercu-
losis, for doctors and nurses caring for pa-
tients with drug-resistant tuberculosis in
clinics, major barriers undermine prompt
diagnosisandreferral.Toimprovetheout-
look for patients in South Africa with
drug-resistant tuberculosis, the NYC ex-
perience suggests some crucial invest-
ments that should be considered in the1730 • CID 2008:46 (1 June) • Murphy
short term, including (1) the creation of
enough MDR-TB and XDR-TB treatment
capacity such that, after microbiological
diagnosis, therapy can begin immediately;
(2) the development of improved labo-
ratory capacity to guarantee rapid, accu-
rate, and accessible results of culture and
susceptibility tests; (3) the creation of a
public health infrastructure capable of en-
suring that patients complete tuberculosis
therapy; and (4) the institution of mea-
sures in hospitals and clinics to decrease
the nosocomial transmission of drug-re-
sistant tuberculosis.
EXPANDING TREATMENT
CAPACITY
One very important lesson from the NYC
outbreak of MDR-TB was that, in HIV-
infected hosts, MDR-TB follows an ac-
celerated course and has a very high case-
fatality rate [2]. However, evidence from
the NYC epidemic also shows that out-
comes, at least for patients with MDR-TB,
can be better when active, second-line
agents are promptly initiated [2, 4]. Al-
though not yet well studied, XDR-TB(de-
ﬁned as infection withM. tuberculosiswith
resistance to isoniazid and rifampicin as
well as resistance to any ﬂuoroquinolone
and 1 of the second-line injectableagents)
in patients with HIV infection may follow
the same essential principle. It is therefore
vital, during the short window of time
when second-linetuberculosistherapycan
improve clinical outcomes—for patients
such as Precious Cele—that it not be
delayed.
A particularly urgent issue in South Af-
rica involves how to expand second-line
treatment capacity to prevent potentially
avoidable deaths and ongoing transmis-
sion from untreated disease. If the inpa-
tient model is used, expansion of capacity
will be slow and expensive, and queues
may remain the mechanism by which sec-
ond-line treatment is allocated. An im-
portant alternative model for South Africa
to consider for selected patients is com-
munity-based treatment of drug-resistant
tuberculosis. Compelling data that sup-
port community-based treatment for
drug-resistant tuberculosis—by use of
peer support and multidisciplinary
teams—have been generated in other re-
source-constrained settings, which sug-
gests that such a model can be both cost-
effective and efﬁcacious [5]. Furthermore,
outpatient models can be scaled up
quickly as the need escalates and can in-
clude antiretroviral therapy (160% of pa-
tients in South Africa with tuberculosis
have concomitant HIV infection), and re-
sources can be reallocated for other pur-
poses once the crisis abates.
IMPROVING LABORATORY
INFRASTRUCTURE
The rapid initiation of second-line treat-
ment for patients infected with drug-re-
sistant M. tuberculosis in South Africa will
depend on a close relationship between
doctors and mycobacterial laboratories.
Although South Africa has the beneﬁt of
more facilities for culture and sensitivity
testing than any other sub-Saharan Afri-
can nation, the increased demandscreated
by the current epidemic of drug resistance
have stretched this hard-working sector
and have highlighted its limitations. Cur-
rently, delays in the reporting of results
and difﬁculties in locating data for indi-
vidual patients hinder the early diagnosis
and rapid referral of patientsfortreatment
of MDR-TB and XDR-TB, which directly
affect patient outcomes. As the epidemic
escalates, thenumberofclinicalspecimens
that South Africanlaboratorieswillreceive
willvastlyincrease.Investmentsmadenow
will help laboratories to handle this ele-
vated demand more efﬁciently and accu-
rately.Ifclinicallaboratoriesaresupported
and improved, they can also become im-
portant platformsfortestingvariousnovel
diagnostics that may ultimately shorten
the timeneededtodiagnosedrug-resistant
tuberculosis.
ENSURING TREATMENT
COMPLETION
Leading up to the growth ofdrug-resistant
tuberculosis, both NYC and South Africa
experienced an underinvestment in
the vital public health infrastructure
needed to ensure completion of tuber-
culosis treatment among patients [6]. The
implications of this underinvestment in
NYC were vividly illustrated by a study at
Harlem Hospital, conducted early in the
outbreak, which showed that, among 178
patients discharged with standard tuber-
culosis treatment in 1988, only 11% com-
pleted it [7]. Similarly, each year, South
Africa reports 1400,000 cases of tuber-
culosis, but high rates of default and loss
to follow-up result in a low treatment-
success rate of only 70% [8]. The lowest
rates of treatment completion are found
in the province of KwaZulu-Natal—not
coincidently, the apparent epicenter of
drug-resistant tuberculosis in South Af-
rica [3]. Indeed, for patients with resis-
tant disease, the need for intensive ad-
herence support and close patient
follow-up is especially great because sec-
ond-line therapy is associated with more
adverse effects and requires a longer
treatment course. Moreover among pa-
tients with MDR-TB and XDR-TB, the
implications of treatment default for
both the individual and society are par-
ticularly grave.
In NYC, the expansion of directly ob-
served therapy with community-outreach
workers and intensive case management
was associated with marked improve-
ments in the incidence of tuberculosisand
rates of drug resistance [9]. At the clinic
level, programs that were particularly ef-
fective were “patient-centered” and in-
cluded relevant incentives and peer-based
support [10, 11]. Likewise, an improve-
ment in treatment adherence and a re-
duction in the number of new cases of
drug-resistant tuberculosisinSouthAfrica
will require a strong commitment from
central health authorities and a rethinking
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is delivered at the most local levels. In
South Africa, patient-centeredapproaches
that include peer support (already used
with great success in the antiretroviral
therapy rollout sector) and relevant in-
centivescouldimproveadherencetotreat-
ment. A commitment by health authori-
ties and by local clinics topatient-centered
strategies may result in higher rates of
treatment completion (and may reduce
the incidence of drug resistance), because
such approaches address, rather than ig-
nore, the difﬁcult social and economiccir-
cumstances in which tuberculosis is most
commonly encountered.
CONFRONTING NOSOCOMIAL
TRANSMISSION
In NYC, it was demonstrated that, among
hospitalized HIV-infected patients, drug-
resistant tuberculosiscanspreadefﬁciently
[12]. Furthermore, patients infected with
drug-susceptible strains who enter health
care settings can be reinfected with drug-
resistant strains [13]. Although no longer
in existence in NYC, tuberculosiswards—
comprised almost entirelyofHIV-infected
patients—remain commonplace in South
Africa (and throughout sub-Saharan Af-
rica), and few experts were surprised to
learn that the majority of patients with
XDR-TB in Tugela Ferry, South Africa,
had recently been admitted to a hospital
[3]. Outpatient clinics are another keyset-
ting where drug-resistant tuberculosis can
be transmitted [14]. At antiretroviralther-
apy rollout clinics and outpatient depart-
ments in South Africa, it is common for
immunocompromised patients like Pre-
cious Cele to line up for hours in poorly
ventilated rooms. The nosocomial trans-
mission of drug-resistant M. tuberculosis
in hospital wards and outpatient clinics is
undoubtedly contributing to the current
crisis in South Africa. It is imperative that
current tuberculosis infection-control
protocols in South Africa be redesigned in
cost-effective ways. In addition to recon-
sidering the practice of clustering patients
with suspectedtuberculosisinopenwards,
other steps potentially within reach in-
clude (1) the separation and prioritized
evaluation of patients who present as out-
patients with symptoms compatible with
tuberculosis, (2) the implementation of
basic environmental controlsinwardsand
waiting areas to ensure the circulation of
outside air (or the treatment of recircu-
lated air), (3) the isolation of patientswith
suspected or deﬁnitive drug-resistant tu-
berculosis, and (4) the provision of respi-
ratory protection devices for medical staff
involved in the care of patients with tu-
berculosis [15]. Medical staff, with the
support of occupational health depart-
ments, should be offered voluntary HIV
testing, and HIV-infected staff should be
offered access to early antiretroviral ther-
apy,aswellaspositionsthatdonotinvolve
close contact with patients with tu-
berculosis.
CONCLUSIONS
In the face of MDR-TB and XDR-TB,
South Africa has acted rapidly and ad-
mirably, but more must be done. South
Africa must rededicate itself to the task of
tuberculosis control and treatment with a
rapid, multifaceted approach. This must
include expansion of second-line treat-
ment capacity, investment in clinical lab-
oratories, assurance of supervised adher-
ence support for all patients, and
enhancement of infection control proce-
dures. In NYC, similar steps were suc-
cessful in leading to the rapid decrease in
rates of drug resistance [9]. With reﬁne-
ments based on local resource constraints,
these measures could potentiallyarrestthe
alarming growth of MDR-TB and XDR-
TBinSouthAfrica.Unlikemanycountries
in sub-Saharan Africa, South Africa has
the capacity to mount a rapid and large-
scale response before drug-resistant tu-
berculosis envelops a much larger and
poorer region. Support for South Africa’s
efforts from donor nations is a moral im-
perative and will avoid the erosion of
hard-won gains that have accrued since
the antiretroviral therapy rollout.
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